Abbott India Q1 Results: Revenue Reaches ₹18.14 Billion

MUMBAI, India — Abbott India Limited reported a solid financial performance for the first quarter ended June 30, 2026, recording revenue from operations of ₹18.14 billion (₹1,813.68 crore).

The Mumbai-headquartered pharmaceutical giant posted a net profit of ₹4.29 billion (₹428.52 crore) for the quarter. Alongside the financial results, the company's Board of Directors announced major leadership changes, approving the appointment of Sudarshan Jain as Chairman following the stepping down of Munir Shaikh.

Leadership Transition and Board Decisions

In a regulatory filing submitted to the BSE Limited, Abbott India confirmed that Non-Executive Director Munir Shaikh stepped down from the position of Chairman of the Board of Directors effective at the close of business hours on August 12, 2026.

Based on recommendations from the Nomination and Remuneration Committee, the board appointed Sudarshan Jain, an Independent Director on the board, as the new Chairman effective August 13, 2026. The board meeting, held at the company's corporate premises in Mumbai, commenced at 3:30 PM IST and concluded at 6:25 PM IST on August 12, 2026.

Revenue and Financial Performance Overview

During the April–June quarter of FY 2026–27, Abbott India reported total income of ₹18.89 billion (₹1,889.05 crore), which includes revenue from operations of ₹18.14 billion (₹1,813.68 crore) and other income of ₹753.7 million (₹75.37 crore). In the corresponding quarter of the previous year (Q1 FY26), operations revenue stood at ₹17.38 billion (₹1,738.35 crore).

Total expenses for the quarter rose to ₹13.17 billion (₹1,316.84 crore), compared to ₹13.18 billion in the year-ago period. Cost of materials consumed accounted for ₹1.51 billion, while stock purchases in trade stood at ₹8.12 billion. Employee benefit costs totaled ₹1.75 billion for the period.

The company's profit before tax reached ₹5.72 billion (₹572.21 crore), compared to ₹4.93 billion (₹493.13 crore) in Q1 FY26. Total tax expenses for the quarter were recorded at ₹1.44 billion (₹143.69 crore).

Regulatory Compliance and Sector Impact

Abbott India's financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) under Section 133 of the Companies Act, 2013. Statutory auditor Walker Chandiok & Co LLP completed a limited review of the quarterly statements under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, issuing an unmodified review report.

The company operates exclusively in a single segment, Pharmaceuticals, making segment-wise disclosures non-applicable under regulatory norms. The steady earnings growth reflects continued demand across core therapeutic areas in India's healthcare sector.

Official Sources Section

Financial information, executive appointments, and corporate updates mentioned in this report are based on official stock exchange disclosures filed by Abbott India Limited with the BSE Limited and the National Stock Exchange of India Limited on August 12, 2026.

Quote Section

According to official filings signed by Company Secretary Sangeeta Shetty, the Board of Directors approved the un-audited financial results and leadership appointments during its meeting on August 12, 2026.

Organizers stated in regulatory notices that Sudarshan Jain assumes the role of Chairman of the Board of Directors starting August 13, 2026, following the departure of Munir Shaikh at the close of business on August 12, 2026.

Why It Matters

Abbott India's performance reflects resilience in the domestic healthcare sector amid broader market shifts. The executive transition brings Sudarshan Jain, an industry veteran, to lead the board as the enterprise continues expanding its domestic pharmaceutical footprint, impacting retail consumers, institutional buyers, healthcare professionals, and stock market investors tracking multinational pharma firms in India.

Key Facts at a Glance

• Q1 Revenue from Operations: ₹18.14 billion (₹1,813.68 crore).

• Q1 Net Profit: ₹4.29 billion (₹428.52 crore).

• New Chairman: Sudarshan Jain appointed Chairman effective August 13, 2026.

• Outgoing Chairman: Munir Shaikh stepped down on August 12, 2026.

• Basic EPS: ₹201.66 per share for the quarter ended June 30, 2026.

Frequently Asked Questions (FAQ)

What was Abbott India's revenue for the quarter ended June 30, 2026?

Abbott India reported revenue from operations of ₹18.14 billion (₹1,813.68 crore) for the first quarter of FY 2026–27.

How much net profit did Abbott India generate in Q1?

The pharmaceutical firm achieved a net profit of ₹4.29 billion (₹428.52 crore) for the quarter.

Who has been appointed as the new Chairman of Abbott India?

Sudarshan Jain, an Independent Director on the board, was appointed Chairman of the Board of Directors effective August 13, 2026.

Why did Munir Shaikh step down as Chairman?

Munir Shaikh stepped down as Non-Executive Chairman effective close of business hours on August 12, 2026, as part of planned board leadership transitions.

Source: Abbott India Limited Outcome of Board Meeting, BSE Limited Corporate Filings, National Stock Exchange of India Limited Corporate Announcements